CHELMSFORD, Mass., April 29, 2015 (GLOBE NEWSWIRE) -- Brooks Automation, Inc. (Nasdaq:BRKS), the global leader in automated cold-chain sample management for drug discovery and biostorage applications, announced the introduction of the BioStore™ III Cryo, an automated cryogenic sample management system. BioStore III Cryo introduces automation to the largest segment of bio-samples being stored, which currently relies on manual cryo storage systems.
BioStore III Cryo incorporates sample monitoring, tracking, and inventory control with the industry's standard cryo storage vessel. The system can access virtually any type of sample within a cryobox format and retrieve a box of samples in less than 60 seconds. Meanwhile, the other samples stored within the liquid nitrogen system are maintained at a temperature below -135° C at all times. The highly ergonomic design and built-in user safety features of the BioStore III Cryo system provide new and significant benefits over traditional, manual cryo storage systems.
"BioStore III Cryo is a new cryogenic storage system that offers sample automation, cold chain management, and improved security and accessibility while maintaining sample protection within a liquid nitrogen environment," said Dusty Tenney, president of Brooks Life Science Systems. "The BioStore III Cryo provides customers who need biological sample storage with a solution that combines the highest sample protection, improved chain of custody management, and a superior user experience - all at an affordable price."
The new system was developed in collaboration with Chart Industries, the leading provider of manual cryo storage systems.
About Brooks Automation, Inc.
Brooks is a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor manufacturing and life sciences. Brooks' technologies, engineering competencies and global service capabilities provide customers speed to market and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market and, through product development initiatives and strategic business acquisitions, has expanded offerings to meet the needs of customers in the life sciences industry, analytical & research markets and clean energy solutions. Brooks is headquartered in Chelmsford, MA, with direct operations in North America, Europe and Asia. For more information, visit www.brooks.com.
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Brooks' financial and business results to differ materially from its expectations. The statements are based on the facts known to the Company's management at the time they are made. These forward-looking statements include statements regarding the expected benefits of the newly announced product and its market acceptance. Please see the factors and other risks that the Company has described in their filings with the Securities and Exchange Commission, including but not limited to the Annual Report on Form 10-K, current reports on Form 8-K and quarterly reports on Form 10-Q. As a result, Brooks cannot provide any assurance that its future results will not be materially different from those projected. Brooks expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Brooks undertake no obligation to update the information contained in this press release.